Indaptus Therapeutics, Inc. Shareholders' Equity
Indaptus Therapeutics, Inc. (INDP) had Shareholders' Equity of $11.37 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-13
- 2026-06-30: Stockholders' Equity Attributable to Parent $11.37M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.25M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $3.15M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $4.61M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $11.37M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $1.25M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | $3.15M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $4.61M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$1.67M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $2.80M 10-Q · filed 2026-08-13 | |
| 2024-12-31 | $3.94M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | $6.00M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $6.17M 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $9.36M 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $12.08M 10-K · filed 2026-03-17 | |
| 2023-09-30 | $15.33M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $18.63M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $21.19M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $24.63M 10-K · filed 2025-03-13 | |
| 2022-09-30 | $27.57M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $30.41M 10-Q · filed 2023-11-06 | |
| 2022-03-31 | $33.36M 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $35.90M 10-K · filed 2024-03-13 | |
| 2021-09-30 | $38.08M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$1.32M 10-Q · filed 2022-11-10 | $13.94M 10-Q · filed 2021-08-16 |
| 2021-03-31 | -$829.68K 10-Q · filed 2022-11-10 | $11.34M 10-Q · filed 2021-08-16 |
| 2020-12-31 | -$237.70K 10-K · filed 2023-03-17 | $14.53M 10-Q · filed 2021-08-16 |
| 2020-09-30 | $513.00 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $2.02M 10-Q · filed 2021-11-15 | $16.18M 10-Q · filed 2021-08-16 |
| 2020-03-31 | $2.69M 10-Q · filed 2021-11-15 | $14.22M 10-Q · filed 2021-08-16 |
| 2019-12-31 | $3.21M 10-K · filed 2022-03-21 | $11.54M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |